Current Funding Announcements

See below

Combat Readiness – Medical Research Program Rapid development and translational research award (RDTRA)

Description: The CRRP focuses on forward-deployable solutions that can promptly address life-

threatening injuries, medical threats, and treatments for Warfighters in current and future

battlefield settings, to deliver high-impact medical solutions in diverse operational settings and

closer to the point of injury to increase survivability and Warfighter readiness. The program seeks

to develop innovative solutions to increase medical readiness, mitigate fatalities, optimally treat

life-threatening injuries, and promote positive long-term outcomes. Innovations developed by

CRRP-supported research may be applied proactively as a way to establish medical readiness ahead of

deployment, in operational settings at the point of injury, during periods of prolonged care, or

during transport/ en route between roles of care.

Focus Areas broadly describe current priorities to improve readiness for delivering frontline care

in combat situations and for delivering medical damage control capability, assets, and life- saving

interventions during prolonged and en route care in austere and combat environments, including the

acute and early management of combat-related trauma at the point of injury.

Proposed research must address at least one of the FY22 CRRP Focus Areas; these include

complementary health measures to accelerate return to duty, and regenerative medicine. Focus areas

include solutions to enhance combat care delivery throughout the far-forward environment, such as:

• Telemedicine solutions that enable medical capabilities at far-forward battlespace locations

worldwide

• Medical simulation technology that supports sustainment of critical skills and medical

decision-making

• Solutions for the assessment of mild traumatic brain injury, to include portable and handheld

devices

Proposed research must have the potential for rapid development and translation of applicable

advances for improving medical readiness, mitigating fatalities, optimally treating life-

threatening injuries, and promoting positive long-term outcomes for military health and medicine,

as well as the general public. Supports preclinical research, clinical research, and small-scale

clinical trials (e.g., first in human, phase 1/1b).

Pre-Application (Preproposal) due: June 23, 2022

Proposal/Application due: September 14, 2022

Max Period of Performance: 2 years (3 years with option)

Max Funding: $2.2M total costs (2 years), $1M option year

For more information, full announcements (extramural, intramural), and submission

instructions: https://cdmrp.army.mil/funding/crrp

Department of Defense Congressionally Directed Medical Research Programs (CDMRP) Hearing Restoration Research Program (HRRP) – Anticipated Funding Opportunities for FY22

PRE-ANNOUNCEMENT: Department of Defense Congressionally Directed Medical Research Programs (CDMRP)

Hearing Restoration Research Program (HRRP) – Anticipated Funding Opportunities for FY22

Description: The FY22 Defense Appropriations Act provides funding for the Hearing Restoration

Research Program (HRRP) to support innovative and impactful research that pursues the treatment of

auditory system injuries and the restoration of hearing. The HRRP is providing the information in

this pre-announcement to allow investigators time to plan and develop ideas for submission to the

anticipated FY22 funding opportunities. This pre-announcement should not be construed as an

obligation by the government. The FY22 HRRP funding opportunity announcements for the following

award mechanisms will be posted on the Grants.gov website. Pre-application and application

deadlines will be available when the announcements are released.

Applications submitted to the FY22 HRRP must address one or more of the following Focus Areas:

• Accelerate translation of biological regeneration/repair mechanisms into therapies that treat

auditory system injury and restore auditory function.

For example, but not limited to:

o Hair cell regeneration/repair/recovery

o Neural regeneration/repair/recovery

o Treatment for synaptopathy and hidden hearing loss

• Diagnostic tests that help differentiate sensory, neural, synaptic, and central processing

disorders, that may inform applicability and outcomes for current or future hearing restoration

therapeutics.

• Develop reliable in-vitro human models to facilitate the understanding, derivation and

characterization of human auditory cells, and/or to facilitate the evaluation of hearing

restoration therapies.

• Develop and/or validate techniques/methods beyond the audiogram to diagnose acute auditory

system injury in austere or remote environments. For example, but not limited to, simple and rapid

assessments that are compatible with portable platforms.

A pre-application is required and must be submitted through the electronic Biomedical Research

Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All

applications must conform to the final funding opportunity announcements that will be available for

downloading from the Grants.gov website. The application package containing the required forms for

each award mechanism will also be found on Grants.gov.

Pre-announcement news release: https://cdmrp.army.mil/pubs/press/2022/22hrrppreann

About HRRP: https://cdmrp.army.mil/hrrp/default

Maximum funding/periods of performance
Funding level 1: $250,000/2 years
Funding level 2: $1M/3 years

Funding level 3: $1.25M/3 years

Point of Contact: CDMRP Public Affairs, 301-619-9783, usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

FY22 Department of Defense, Defense Health Program, Congressionally Directed Medical Research Programs (CDMRP) Joint Warfighter Medical Research Program (JWMRP) Military Medical Research and Development Award (MMRDA)

W81XWH-22-S-JWMRP/ W81XWH-22-JWMRP-MMRDA: FY22 Department of

Defense, Defense Health Program, Congressionally Directed Medical Research Programs (CDMRP) Joint

Warfighter Medical Research Program (JWMRP) Military Medical Research and Development Award (MMRDA)

Description: The JWMRP was initiated in 2012 to augment and accelerate high-priority Department of

Defense (DOD) and Service medical requirements and to continue prior year initiatives that are

close to achieving their objectives and yielding a benefit to military medicine. The ultimate goal

of the program is to expedite the delivery of highly impactful medical solutions to Service Members

and Military Health System (MHS) beneficiaries. Funds from the JWMRP shall not be used for new

projects or for basic research.

To be eligible for JWMRP funding, applicants must have already received DOD core or DOD

Congressional Special Interest prior year funding (including DOD Small Business Innovation

[SBIR]/Small Business Technology Transfer [STTR] awards) for the same project proposed for

continuation under this MMRDA.

Focus Areas of interest include:

• Operational Medicine and Readiness

o Research aimed toward injury prevention, rapid return-to-duty capabilities, and rehabilitation

solutions to maintain Service Member readiness (musculoskeletal and neurosensory)

o Mechanism-based criteria and injury prediction models for ballistic and/or blast- induced head

injuries from a wide range of loading regimes seen with current and likely future weapons systems,

with the goal of informing the development of more effective helmet protection

Find information for extramural and intramural applicants at: https://cdmrp.army.mil/funding/jwmrp

Pre-Application (Preproposal) Deadline: May 16, 2022

Application Deadline: July 28, 2022 11:59 p.m. ET

Maximum funding: $4.5 million for total costs

Maximum period of performance: 3 years

CDMRP Help Desk: help@eBRAP.org

FY22 CDMRP Peer Reviewed Medical Research Program Awards

W81XWH-22-PRMRP – FY22 CDMRP Peer Reviewed Medical Research Program

Awards

• Clinical Trial Award (CTA)

• Discovery Award (DA)

• Focused Program Award (FPA)

• Investigator-Initiated Research Award (IIRA)

• Technology/Therapeutic Development Award (TTDA)

Description: The PRMRP is committed to supporting research that has the potential to profoundly

impact the development and implementation of medical devices, drugs, and clinical guidance that

will enhance the precision and efficacy of prevention, diagnosis, and treatment across a wide range

of disciplines including autoimmune diseases and immunology, cardiovascular health, endocrine

health and metabolism, environmental health, infectious diseases, internal medicine, neurological

and psychological health, orthopedic and regenerative medicine, and respiratory health and injury.

FY22 PRMRP Portfolio Categories/Topic Areas/Strategic Goals include Neuroscience /Trauma:

• Foundational Studies: mechanisms underlying neurological diseases and psychological

conditions including potential relationships to environmental/neurotoxic exposures, injury, stress,

or infections

• Prevention: strategies, including predictive analytics and artificial intelligence, to

provide early identification of associated neurological diseases and psychological conditions, with

the goal of providing early intervention; tools to reduce complications of physical and/or

psychological trauma

• Treatment: novel treatments, strategies or therapeutic targets, including research to

repurpose existing drugs, for associated neurological diseases and psychological conditions;

capabilities to monitor, and therapies or countermeasures to maintain, optimal cognitive

functioning and mental resilience; treatment strategies to manage symptoms and improve quality of

life for those affected by associated neurological and psychological conditions

• Epidemiology: population-based studies to identify risk factors (e.g., military-specific

lifestyle) that contribute to onset and progression of associated neurological diseases and

psychological conditions

Program announcements, instructions, and pre-application: https://cdmrp.army.mil/funding/prmrp

All pre-applications must be submitted electronically to the Electronic Biomedical Research

Application Portal (eBRAP) https://ebrap.org. Full applications must be submitted electronically to

the Grants.gov website https://grants.gov.

BRAIN Initiative: Targeted BRAIN Circuits Projects – Targeted BCP (R01 Clinical Trial Not Allowed)

RFA-NS-22-026: BRAIN Initiative: Targeted BRAIN Circuits Projects – Targeted BCP (R01

Clinical Trial Not Allowed)

Description: This FOA solicits applications for research projects that seek to understand how

circuit activity gives rise to mental experience and behavior using innovative, methodologically-

integrated approaches. The goal is to support adventurous projects that can realize a potentially

transformative outcome within 5 years. Applications are expected to address circuit function in the

context of specific behaviors or neural systems, such as sensation, perception, attention,

reasoning, intention, decision-making, emotion, navigation, communication, or homeostasis. Projects

should link theory, data analysis, and/or computational approaches to experimental design and

should produce predictive models (conceptual or quantitative).

Projects should aim to improve the understanding of circuits of the central nervous system by

systematically controlling stimuli and/or behavior while actively recording and/or manipulating

dynamic patterns of neural activity. Diverse species or experimental systems and a cross-

species/comparative approach are welcome and should be chosen based on their power to address the

specific question at hand and to reveal generalizable and fundamental neuroscience principles.

Targeted BRAIN Circuit Project R01 awards will support an individual laboratory or a small

multi-PD/PI team. Projects should reflect the NIH BRAIN Initiative interests of the application of

cutting-edge methodologies to understand central nervous system circuit function and

dynamics at cellular and sub-second levels of resolution in ethologically relevant behaviors of an

organism or a well-defined neural system. Applications should offer specific, feasible, and

potentially transformative research goals as endpoints within a 5-year term

Representative topics include: Innovative approaches to understand network coding of sensory

information and/or multi-sensory integration, at multiple stages of processing, in response to

naturalistic inputs and perceptual contexts.

Letter of Intent due date(s) 30 days prior to the application due date

Application due dates: June 1, 2022; July 1, 2022; October 6, 2022; June 30, 2023; October 4,

2023; June 28, 2024; October 2, 2024

Maximum project period: 5 years

Funding amount: the BRAIN Initiative intends to commit up to an estimated total of $15 M per year

to fund 20 awards.

Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-026.html

American Hearing Research Foundation Discovery Grants

American Hearing Research Foundation: Hearing and Balance Disorders of the

Inner Ear and Related Topics

Description

AHRF Discovery Grants (formerly called Regular Grants) funds studies that investigate various

aspects of hearing and balance disorders related to the inner ear. AHRF typically funds six to ten

Discovery Grants each year. Priority is given to investigators early in their careers who need seed

funds to generate results and data that can be used to support applications for larger grants

(i.e., NIH grants) in the future.

The Birtman Grant may be awarded for exceptional scientific investigation when AHRF identifies a

study that shows outstanding promise.

Both basic and clinical studies may be proposed that investigate aspects of the auditory and

vestibular systems including but not limited to:

• genetics

• neurotology

• anatomy

• auditory processing

• molecular and cellular biology

• therapeutic studies

• investigations of current or experimental devices (i.e., cochlear implants)

AHRF donors have given special support for research that explores Meniere’s disease (mechanisms,

causes, or treatments) and the causes or mechanisms of sudden hearing loss. Proposals that address

these areas of interest will receive special consideration during the review process.

Applicants must hold an MD, PhD, AuD, or equivalent degree(s) and be associated with a university

or hospital in the United States.

Next deadline: August 16, 2021

Maximum Project Period: 1 year (1/1/2022 – 12/31/2022)

Maximum Amount: $50,000 (Discover Grant), $75,000 (Birtman Grant)

Additional Information: https://www.american-hearing.org/research-grants/grants-we-offer/

https://www.american-hearing.org/research-grants/grant-process/

NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01 Clinical Trials Optional)

RFA-DC-22-001: NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01 Clinical Trials Optional)

NIH - National Institute on Aging (NIA) and National Institute on Deafness and Other Communication

Disorders (NIDCD)

Description: This Funding Opportunity Announcement (FOA) is intended to provide an avenue for basic

scientists, clinicians and clinical scientists to jointly initiate and conduct translational

research projects which translate basic research findings into clinical tools for better human

health. The scope of this FOA includes a range of activities to encourage translation of basic

research findings which will impact the diagnosis, treatment and prevention of communication

disorders. Connection to the clinical condition must be clearly established and the outcomes of

the grant must have practical clinical impact.

Possible goals include, but are not limited to:

• Biochemical, electrophysiological and behavioral assays to enhance diagnostic capabilities.

• Pharmacology, toxicity, and pharmacokinetic for candidate therapeutics that have demonstrated

potential for the treatment of communication disorders.

• Preclinical animal research for dosage studies and toxicity when a subsequent Phase I/II

clinical trial is planned.

• Translation of new tools and techniques for better diagnostics or therapeutics, including but

not limited to, neuroprosthetic devices, drug delivery devices, neuro-electrical stimulators and

recording devices.

• Translation of laboratory-based screening tests, including biomarkers into improved ways to

identify individuals at risk for a communication disorder to allow for early intervention.

• Translation of published basic research findings into new clinical tools to better target the

treatment to the individual patient and to better predict patient response or prognosis.

• Translation of discoveries from biological, psychological, social sciences and other related

areas into innovative prevention and treatment paradigms and processes.

• Modification of laboratory measures of function or laboratory treatment protocols for use in

clinical settings.

Open Date (Earliest Submission Date): September 17, 2021

Letter of Intent Due Date(s): 30 days prior to the application due date

Application Due Date(s): October 20, 2021; June 20, 2022; February 22, 2023; October 18,

2023; June 20, 2024

Maximum Project Period: 5 years

Maximum Amount: NIDCD anticipates funding an estimated 2-3 awards in fiscal year 2022 for a total

of $1,500,000.

additional Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-22-001.html

Open/Active DoD Broad Agency Announcements

U.S. Army Medical Research and Development Command (USAMRDC) - W81XWH18SBAA1: This BAA is open through September 30, 2022. USAMRDC funds a broad range of extramural research programs through contracts, grants, or cooperative agreements. Proposals can be submitted through the USAMRDC Broad Agency Announcement (BAA) or through special USAMRDC BAA Announcements, which are open for limited timeframes. Additional information, the USAMRDC Broad Agency Announcement, and open special USAMRDC BAA Announcements can be obtained at: https://www.usamraa.army.mil/Pages/BAA.aspx and https://www.grants.gov/web/grants/view-opportunity.html?oppId=297726

U.S. Air Force/AFRL - 711 HPW BAA: The Airman Readiness Medical Research (ARMR) Hybrid Broad Area Announcement (BAA) was released May 1, 2020, and will remain open for 72 months for medical research to optimize the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective aims to: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance.

See: https://beta.sam.gov/opp/31a536d407cd4d519fc89ffd3366cbb3/view?keywords=AirmanReadinessMedicalResearch(ARMR)&sort=relevance&index=&is_active=true&page=1

U.S. Air Force/AFRL - BAA-AFRL-RQKHC-2016-0009 Aerospace Medicine, Clinical Research, Human Performance Research, and Expeditionary Medicine: This BAA will remain open for seventy-two (72) months with calls being released throughout the seventy-two (72) month period of performance. The Air Force Research Laboratory (AFRL) 711 Human Performance Wing in the School of Aerospace Medicine and Human Systems Integration Directorate solicits innovative research proposals in the following five research areas.
1. Force Health Protection – Focus on research to prevent injury and illness and the early recognition or detection of emerging threats. 2. EN Route Care –Continuum of care during transport of patients from point of injury to point of definitive care.
3. Operational Medicine (OM) – Air Force Medical Service (AFMS) sponsored OM encompasses interest in definitive diagnosis, care, and treatment in-garrison, to ensure the highest quality of healthcare for active duty members and their families.
4. Expeditionary Medicine - Improving expeditionary medical care during contingency operations including medical countermeasures against combat and operational stressors to maximize warrior health, performance, and well-being.
5. Human Performance and Systems Integration - Maximizing operational human performance for a fit and healthy force.

See: https://beta.sam.gov/opp/4eebfe8f580a41e8a32ba4eae5920342/view?keywords=AerospaceMedicine,ClinicalResearch,HumanPerformanceResearch,andExpeditionaryMedicine&sort=-relevance&index=&is_active=true&page=1

U.S. Military Academy Broad Agency Announcement - W911NF-20-S-0008: This BAA was released April 1, 2020, and is open until March 31, 2025. It seeks proposals for cutting- edge innovative research that could produce discoveries with significant impact to enable new and improved Army technologies and related operational capabilities in the areas of socio-cultural; information technology; ballistics, weapons and protections; energy and sustainability; materials, measurements, and facilities; unmanned systems and space; human support systems; and artificial intelligence, machine learning, and quantum technologies. The human support systems focus includes biomechanical engineering to enhance soldier readiness (human performance optimization, injury prediction/prevention, physical and cognitive augmentation, Return-to-Duty metrics, functional influence of prosthetics/exoskeletal devices) and wearable technologies and sensors to inform performance decisions (e.g., monitoring/assessment, injury prevention, recovery times).

See: Military Academy BAA

NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders

NOT-DC-20-008: NIDCD is Interested in Supporting Research on the Impact of

COVID-19 on Mission Specific Sensory and Communication Disorders

Notice of Special Interest (NOSI) issued by the National Institute on Deafness and Other

Communication Disorders (NIDCD) (see: https://grants.nih.gov/grants/guide/notice-files/NOT-DC20-008.html)

NIDCD invites applications for research on COVID-19 in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech, and language. Given the early stage of COVID19 research, it is critical that there is a strong premise for research proposals submitted in response to this NOSI. When appropriate, NIDCD encourages multi-disciplinary approaches to move the research beyond in vitro and animal models. Areas of research encouraged through this NOSI include, but are not limited to:

Short- and long-term effects of COVID-19 on the auditory, vestibular, or olfactory systems
The prevalence, onset, and resolution of acquired deficits (i.e. HBTSVSL) among patients
with COVID-19 across the lifespan and in association with various underlying genetic predispositions and health conditions
Potential ototoxicity from therapeutics or vaccination related to COVID-19
Worsening of communicative function because of physical distancing, sheltering in place,
and wearing of protective personal equipment during mitigation of this infectious pandemic
Telehealth service delivery to individuals with communication disorders
Multidisciplinary collaborative teams including clinicians, basic biologists, geneticists,
quantitative scientist, epidemiologists, or other researchers to study COVID-19 related
human conditions and behaviors, bioethical considerations, health-service delivery,
health services in low-resource areas, and health disparities within NIDCD mission areas

This notice applies to due dates on or after October 5, 2020 and subsequent receipt dates through September 8, 2022. Submit applications for this initiative using one of the following funding opportunity announcements or any reissues of these announcement through the expiration date of this notice: PA-18-334, PA-20-185, PA-20-184, PA-20-196, PA-20-195, PA-20-194, PA-19-270, PA-19-271, PA-19-273, PA-19-272.

For funding consideration, applicants must include “NOT-DC-20-008” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Scientific/Research Contact:

Bracie Watson, Jr. Ph.D.

NIDCD/Division of Scientific Programs

Telephone: 301-402-3458

Email: watsonb@nidcd.nih.gov

broad agency announcement (baa) for extramural biomedical research and development

Announcement: Grant

Title: BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical Research and Development

Award Organization: USSOCOM

Type/Mechanism: Grant

Funding Opportunity Number: W81XWH-18-S-SOC1

Web Site: DoD : https://www.grants.gov/web/grants/view-opportunity.html?oppId=307754

Expected Number of Awards: 2

Period of Performance: 2 years

Open App: 1 Aug 2018

Close App: 31 Jul 2023

Description: A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel (medical devices, drugs, and biologics) for early intervention in life-threatening injuries, prolonged field care (PFC), human performance optimization, and canine medicine/performance. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. The equipment must be easy to use, require minimum maintenance, and have low power consumption. Drugs and biologics should not require refrigeration or other special handling. All materiel and related techniques must be simple and effective, and easily modified for commercialization.

Research areas of interest include:

• Canine Medicine:

o Sensory Optimization and Protection: The proposed project must develop research oriented toward innovative methods that enhance or conserve SOF canine olfactory, visual, and/or auditory performance during combat operations.

Max Funding: Most projects are anticipated to have a total cost at or below $700,000 (including indirect costs). Projects that have a total cost higher than $700,000 (including Indirect costs) with outstanding scientific merit that meet a critical need may be accepted; however the total cost of these projects are not to exceed $1,500,000 (including Indirect costs). No budget will be approved by the Government exceeding $1,500,000 (including indirect costs).

Research Interests of the Air Force Office of Scientific Research

Announcement: BAA-AFRL-AFOSR-2016-0007
Award Organization: Air Force Office of Scientific Research
Type/Mechanism: Grant
Activity Code:
Web Site: DoD: http://www.grants.gov/web/grants/view-opportunity.html?oppId=285269
Award Amount: $200,000 - $400,000 encouraged; $7.5M max

PoP: 5 years
Restrictions: None
Rolling Annual Programs: Open until Superseded
Pre-Application Due: Open until superseded
Full App Due: Open until superseded
Notes: For the sensory systems portion of the portfolio a goal is to pursue new capabilities in acoustic analysis, to enhance the intelligibility and usefulness of acoustic information. The primary approach is to discover, develop, and test principles derived from an advanced understanding of cortical and sub-cortical processes in the auditory brain. Included are efforts to model and control effects of noise interference and reverberation, understand the psychoacoustic basis of informational masking, develop new methods for automatic speech detection, classification, and identification, and enable efficient 3D spatial segregation of multiple overlapping acoustic sources.

DOD USAMRMC FY18-FY22 Broad agency announcement for extramural medical research

Announcement: W81XWH18SBAA1
Award Organization: U.S. Army Medical Research and Material Commnad's
Type/Mechanism: Grants Notice
Activity Code: USC, Title 10, Section 2358
Web Site: https://www.grants.gov/web/grants/search-grants.html?keywords=W81XWH18SBAA1
Award Amount:
PoP: 4 years
Restrictions:
Rolling Annual Programs:
Pre-Application Due: Oct 1, 2017
Full Application Due : September 30, 2022, 11:59 p.m. ET
Notes: Clinical and Rehabilitative Medicine Research Program focus on the innovations required to reset our wounded Service members, both in terms of duty performance and quality of life. Innovations developed from CRMRP-supported research efforts are expected to improve restorative treatments and rehabilitative care to maximize function for return to duty (RTD) or civilian life.
The CRMRP focuses its efforts on the following research areas: neuromusculoskeletal injury (including limb trauma and amputation), sensory systems impairment (including hearing, balance, tinnitus, and vision), acute and chronic pain, and regenerative medicine.

Research

Quick Fact

#32

Hearing loss can result from exposure to loud noise, physical injury, ototoxic medications, or illness or disease.